{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:53:10Z","timestamp":1781826790474,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50426-0","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:13:46Z","timestamp":1777058026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China"],"prefix":"10.1038","volume":"16","author":[{"given":"Xuexing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"5","key":"50426_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony, S., Stahl, M., Stone, R. M., Acute Myeloid, L. & 2025 Update on diagnosis, risk-stratification, and management. Am. J. Hematol. 100 (5), 860\u2013891 (2025).","journal-title":"Am. J. Hematol."},{"issue":"7","key":"50426_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl. J. Med. 383 (7), 617\u2013629 (2020).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"50426_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz, K. W. et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am. J. Hematol. 99 (4), 615\u2013624 (2024).","journal-title":"Am. J. Hematol."},{"issue":"12","key":"50426_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140 (12), 1345\u20131377 (2022).","journal-title":"Blood"},{"issue":"12","key":"50426_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei, A. H., Loo, S. & Daver, N. How I treat patients with AML using azacitidine and venetoclax. Blood 145 (12), 1237\u20131250 (2025).","journal-title":"Blood"},{"issue":"2","key":"50426_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea, D. A. et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am. J. Hematol. 96 (2), 208\u2013217 (2021).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"50426_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti, A. et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106 (3), 894\u2013898 (2021).","journal-title":"Haematologica"},{"issue":"11","key":"50426_CR8","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat, N. et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 108 (11), 3170\u20133174 (2023).","journal-title":"Haematologica"},{"issue":"11","key":"50426_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135 (11), 791\u2013803 (2020).","journal-title":"Blood"},{"issue":"1","key":"50426_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133 (1), 7\u201317 (2019).","journal-title":"Blood"},{"issue":"13","key":"50426_CR11","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva, M. et al. Impact of FLT3 Mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia. Clin. Cancer Res. 28 (13), 2744\u20132752 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"50426_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.25929","volume":"95","author":"I Aldoss","year":"2020","unstructured":"Aldoss, I. et al. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am. J. Hematol. 95 (10), 1193\u20131199 (2020).","journal-title":"Am. J. Hematol."},{"issue":"2","key":"50426_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21 (2), 178\u2013184 (2015).","journal-title":"Nat. Med."},{"issue":"4","key":"50426_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27231","volume":"99","author":"Y Abaza","year":"2024","unstructured":"Abaza, Y. et al. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. Am. J. Hematol. 99 (4), 606\u2013614 (2024).","journal-title":"Am. J. Hematol."},{"issue":"2","key":"50426_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat, N. et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am. J. Hematol. 99 (2), 193\u2013202 (2024).","journal-title":"Am. J. Hematol."},{"issue":"10","key":"50426_CR16","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat, N. et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica 107 (10), 2501\u20132505 (2022).","journal-title":"Haematologica"},{"issue":"7","key":"50426_CR17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108 (7), 1768\u20131781 (2023).","journal-title":"Haematologica"},{"issue":"2","key":"50426_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/jcm13020584","volume":"13","author":"T Chatzilygeroudi","year":"2024","unstructured":"Chatzilygeroudi, T. et al. Real-life multicenter experience of venetoclax in combination with hypomethylating agents in previously untreated adult patients with acute myeloid leukemia in Greece. J. Clin. Med. 13 (2), 584 (2024).","journal-title":"J. Clin. Med."},{"issue":"1","key":"50426_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto, K. et al. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J. Clin. Oncol. 52 (1), 29\u201338 (2022).","journal-title":"Jpn J. Clin. Oncol."},{"issue":"12","key":"50426_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia, E. et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am. J. Hematol. 95 (12), 1511\u20131521 (2020).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"50426_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","volume":"27","author":"P Vachhani","year":"2022","unstructured":"Vachhani, P. et al. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist 27 (11), 907\u2013918 (2022).","journal-title":"Oncologist"},{"issue":"1","key":"50426_CR22","doi-asserted-by":"publisher","first-page":"2293512","DOI":"10.1080\/16078454.2023.2293512","volume":"29","author":"J Cui","year":"2024","unstructured":"Cui, J. et al. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Hematology 29 (1), 2293512 (2024).","journal-title":"Hematology"},{"issue":"3","key":"50426_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba, M. et al. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann. Hematol. 102 (3), 541\u2013546 (2023).","journal-title":"Ann. Hematol."},{"issue":"1","key":"50426_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens, C. et al. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J. 15 (1), 68 (2025).","journal-title":"Blood Cancer J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50426-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50426-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50426-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:23:28Z","timestamp":1781825008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50426-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50426"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50426-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8454165\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study represents long term experience with venetoclax plus Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML) in China. Venetoclax dose changes and schedule modifications were associated with longer treatment duration and prolonged overall survival, emphasizing the importance of optimal VEN management for improved patient outcomes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Implications for Practice"}}],"article-number":"19101"}}